| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Cretostimogene grenadenorepvec High-Risk BCG-Naïve Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | — | Oncolytic Viruses | Oncology | ||
Phase 2 data readout example | Cretostimogene grenadenorepvec High-Risk BCG-Naïve Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | — | Oncolytic Viruses | Oncology | ||
Phase 2 data readout example | Cretostimogene grenadenorepvec High-Risk BCG-Naïve Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | — | Oncolytic Viruses | Oncology |
Recent Updates
Recently added Catalysts
CG Oncology, Inc.$68.72
-0.77 (-1.17%)
D 38Pipeline Score Richly Valued Biotech · Clinical
Market Cap
5.67 B
EPS
-2.34
P/E Ratio
-
Value Trade
53.85 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.08 M
R&D Expenses
43.73 M
Operating CF
-56.94 M
Total Assets
1.14 B
Total Liabilities
43.48 M
Equity
1.09 B
D/E Ratio
12,345
-7.15 %
Week
-11.49 %
1 Month
14.87 %
3 Month
59.59 %
6 Month
121.55 %
5 Year
121.55 %
All Time
Cash Data
Cash Position
1.08 B
Monthly Burn
18.98 M
Runway
55.4 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
1.58 M
52 Week Range
23.65 - 75.50
% held by Insiders
34.85 %
% held by Institutions
85.06 %
Enterprise Value
4.60 B
Total Shares
80.71 M
Short %
17.64 %
Float Shares
55.61 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D38
Pipeline Score $205M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 54%
Small Cap (rank 417 of 905)
Percentile RankCG Oncology, Inc. faces pipeline headwinds (38/100), with $315M risk-adjusted pipeline value, led by Cretostimogene Grenadenorepvec in Non Muscle Invasive Bladder Cancer (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cretostimogene Grenadenorepvec Small molecule | Non Muscle Invasive Bladder Cancer | Phase 3 | NCT06111235 | 42% | $168M | ACTIVE NOT_RECRUITING | 557 | AVERAGE | C (53) | Feb 1, 2029 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
cretostimogene grenadenorepvec | high-risk BCG-unresponsive NMIBC,intermediate-risk NMIBC | Phase 3 | 2025-08-11 | |||
cretostimogene grenadenorepvec | high-risk BCG-unresponsive NMIBC,intermediate-risk NMIBC | Phase 3 | 2025-08-11 | |||
cretostimogene grenadenorepvec | high-risk BCG-unresponsive NMIBC,intermediate-risk NMIBC | Phase 3 | 2025-08-11 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CGON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CGON
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CGON
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CGON
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CGON Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CGON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CGONCG Oncology to Present at Upcoming Investor Conferences in June 2026
CG Oncology, Inc. announced that its CEO, Arthur Kuan, will present at two major investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. These presentations aim to enhance investor engagement and showcase the company's focus on bladder cancer therapies.
Read more →CGONCG Oncology to Present at Upcoming Investor Conferences in June
CG Oncology, Inc. has announced that its CEO, Arthur Kuan, will present at two significant investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference in New York and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami. These presentations aim to enhance investor engagement and showcase the company's advancements in bladder cancer therapies.
Read more →CGONSUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
CG Oncology and SUO-CTC have announced the recipients of the second annual NMIBC Research Fellowship. Dr. Patrick Hensley and Dr. Daniel Joyce each received grants of up to $50,000 to advance research in non-muscle invasive bladder cancer. Previous awardees presented their findings at the SUO 2026 Annual Meeting, showcasing significant advancements in the field.
Read more →CGONCG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
CG Oncology reported its Q1 2026 financial results, highlighting a strong cash position of $1.1 billion. The company is on track to complete its BLA submission for HR BCG-unresponsive NMIBC by Q4 2026. Key upcoming milestones include topline data from the Phase 3 PIVOT-006 trial and results from the Phase 2 CORE-008 trial, both expected in 2026.
Read more →CGONCG Oncology to Present at Upcoming Investor Conferences in May
CG Oncology, Inc. will present at two upcoming investor conferences in May 2026. CEO Arthur Kuan and COO Ambaw Bellete will participate in fireside chats at the Bank of America Health Care Conference on May 12 and the RBC Capital Markets Global Healthcare Conference on May 20. These events aim to enhance investor engagement and showcase the company's developments in bladder cancer therapies.
Read more →CGONCG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
CG Oncology reported its financial results for 2025 and provided updates on its clinical trials. The company anticipates topline data from the PIVOT-006 Phase 3 trial and CORE-008 Phase 2 trial in the first half of 2026. With a strong cash position, CG Oncology aims to establish cretostimogene as a leading therapy for intermediate-risk and high-risk NMIBC patients. However, the company also reported increased losses and rising expenses.
Read more →CGONCG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
CG Oncology, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Arthur Kuan and COO Ambaw Bellete will lead the presentation, which can be accessed via a live audio webcast. The company aims to develop innovative therapies for bladder cancer patients.
Read more →CGONCG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
CG Oncology has announced an expedited timeline for topline data from the PIVOT-006 Phase 3 trial, now expected in the first half of 2026. This trial evaluates cretostimogene for intermediate-risk non-muscle invasive bladder cancer (NMIBC) and is the first randomized study in this patient group. The rapid enrollment across over 90 sites highlights the urgent need for treatment options in this area.
Read more →CGONNew Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
CG Oncology announced positive topline data from BOND-003 Cohort P and CORE-008 Cohort A, indicating that cretostimogene may serve as a backbone therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The results show high-grade event-free survival rates and a favorable safety profile, with no serious adverse events reported. These findings will be presented at the Society of Urologic Oncology's annual meeting.
Read more →CGONCG Oncology Announces New Board Member and Board Transition
CG Oncology has appointed Christina Rossi to its Board of Directors, enhancing its leadership as it prepares for the launch of cretostimogene, an investigational immunotherapy for bladder cancer. The company also announced the resignation of Simone Song from the board. Rossi brings over 25 years of experience in the pharmaceutical industry, having held senior roles at Blueprint Medicines and Sanofi Genzyme.
Read more →CGONCG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates • Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR
CG Oncology reported its financial results for Q3 2025, highlighting the initiation of a rolling Biologics License Application for cretostimogene in treating high-risk BCG-unresponsive non-muscle invasive bladder cancer. The company demonstrated a significant complete response rate of 41.8% in recent clinical trials and completed enrollment in a major Phase 3 study, PIVOT-006. Financially, CG Oncology maintains a robust cash position, projected to fund operations until mid-2028. However, the company also faces increased operational costs and an escalating net loss compared to the previous year.
Read more →CGONAttacking Bladder Cancer for a Better Tomorrow Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than stat
Crestostimogene grenadenorepvec is an investigational oncolytic immunotherapy currently undergoing clinical trials for Non-Muscle Invasive Bladder Cancer (NMIBC). The therapy shows promising outcomes, with noted high-grade recurrence-free survival rates and favorable safety profiles. However, the success of this candidate is crucial as it is the company's only product in development, with future milestones dependent on clinical trial progress and regulatory approvals.
Read more →CGONCG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
CG Oncology reported promising results from the BOND-003 Cohort C trial, showing a 41.8% complete response rate at 24 months for cretostimogene in patients with high-risk non-muscle invasive bladder cancer. The safety profile remains consistent, with no severe adverse events reported. The data highlights the potential of cretostimogene as a significant treatment option for patients unresponsive to BCG therapy.
Read more →CGONCG Oncology Completes Enrollment in PIVOT-006
CG Oncology has completed enrollment in its Phase 3 PIVOT-006 study, which evaluates the efficacy of cretostimogene grenadenorepvec in patients with intermediate-risk non-muscle invasive bladder cancer. The study aims to address the high recurrence rates and limited treatment options in this patient population. The rapid enrollment reflects a significant unmet need for new therapies in this area.
Read more →CGONCG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
CG Oncology, Inc. announced that its CEO Arthur Kuan and COO Ambaw Bellete will participate in upcoming investor conferences. The company is focused on developing a potential bladder-sparing therapeutic for bladder cancer patients. Interested parties can access the live audio webcast from the company's website.
Read more →CGONCG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
CG Oncology reported strong financial results for Q2 2025, highlighting best-in-disease durability data from the BOND-003 trial for cretostimogene. The company also announced a favorable verdict in its litigation with ANI Pharmaceuticals, allowing it to focus on advancing its bladder cancer treatment. CG Oncology is set to submit a Biologics License Application (BLA) for cretostimogene by the end of the year.
Read more →CGONDelaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
CG Oncology has achieved a unanimous jury verdict in its favor, rejecting ANI Pharmaceuticals' claims for unjust enrichment and future royalties related to the drug cretostimogene grenadenorepvec. The court ruled that ANI is not entitled to any royalties on future sales, allowing CG Oncology to concentrate on its mission to develop therapies for bladder cancer. This decision is viewed as a significant win for patients awaiting innovative treatments.
Read more →CGONCG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
CG Oncology, a late-stage clinical biopharmaceutical company, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. CEO Arthur Kuan will lead a fireside chat, highlighting the company's focus on bladder cancer therapies. The event will be accessible via a live audio webcast.
Read more →CGONCG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
CG Oncology, a late-stage clinical biopharmaceutical company, will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York. The event is scheduled for May 20, 2025, at 11:30 am ET, and will be accessible via a live audio webcast. This participation highlights the company's commitment to advancing treatments for bladder cancer.
Read more →CGONCG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-mo
CG Oncology has reported its financial results for Q1 2025 and updates on its clinical programs. The latest findings from the BOND-003 trial highlight significant durability and tolerability of cretostimogene. Early results from another trial show a promising 90.5% high-grade recurrence-free survival rate. The company plans to submit a Biologics License Application (BLA) for cretostimogene later this year. Despite encouraging data, the company has reported a net loss and rising expenses, suggesting potential financial pressures ahead.
Read more →CGONSUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
CG Oncology and SUO-CTC have announced the recipients of the first annual NMIBC Research Fellowship, aimed at fostering clinical cancer research in non-muscle invasive bladder cancer. Drs. Ghodoussipour and Goodstein were awarded for their promising research plans. The fellowship highlights the commitment to improving bladder cancer treatment and patient outcomes.
Read more →CGONCG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting – Robust 2
CG Oncology has reported promising results for its investigational treatment, cretostimogene grenadenorepvec, at the AUA Annual Meeting. The Phase 3 BOND-003 Cohort C trial showed a robust complete response rate of 42.3% at 24 months, and 97.3% of patients maintained freedom from progression to muscle-invasive bladder cancer. Notably, no severe treatment-related adverse events occurred. Furthermore, early data from Cohort P suggests high-grade recurrence-free survival rates of 90.5% at 3 and 9 months, indicating significant potential for this therapy in the treatment of bladder cancer.
Read more →CGONCG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology presented promising data for cretostimogene grenadenorepvec at the AUA Annual Meeting. The Phase 3 BOND-003 Cohort C study showed a 42.3% complete response rate at 24 months, with 97.3% of patients free from progression to muscle-invasive disease. Cohort P data indicated a 90.5% high-grade recurrence-free survival at 3 and 9 months. The treatment demonstrated a favorable safety profile with no significant adverse events reported.
Read more →CGONCG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Gu rin (BCG)-Unresponsive N
CG Oncology reported its 2024 year-end financial results, highlighting significant progress in its clinical trials for cretostimogene, an investigational therapy for non-muscle invasive bladder cancer (NMIBC). The monotherapy showed a 75.5% complete response rate in high-risk BCG-unresponsive patients, and the company initiated the CORE-008 clinical trial to explore new treatment avenues. Financially, CG Oncology completed an oversubscribed $238 million public equity offering, aiming to extend its operational runway and support ongoing clinical efforts. However, they reported a growing net loss and rising R&D and administrative costs.
Read more →CGONCretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy – Latest BOND-003 data show 75.5% of patients achieved a c
CG Oncology announced that in the Phase 3 BOND-003 study of cretostimogene grenadenorepvec, 75.5% of patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer achieved a complete response. The data presented at the EAU Congress indicate that the median duration of response exceeds 28 months, with no significant adverse treatment-related events reported. Additionally, translational data suggest that no close contact precautions are necessary post-treatment, highlighting the therapy's compelling safety and efficacy profile. Results are expected to further mature as the study continues.
Read more →CGONGroundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer 74.5% of patients achieved a complete res
CG Oncology announced positive topline data from the Phase 3 BOND-003 trial for cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The study showed that 74.5% of patients achieved a complete response, with the median duration of response surpassing 27 months. Notably, there were no severe adverse events reported, which highlights the treatment's safety profile. The findings will be presented at the Society of Urologic Oncology's annual meeting, and the company is optimistic about its potential to transform bladder cancer treatment if approved by the FDA.
Read more →CGONCG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates - Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the
CG Oncology reported its financial results for Q3 2024, highlighting advancements in its treatment pipeline for Non-Muscle Invasive Bladder Cancer (NMIBC). Notably, the late-breaking abstract on the Phase 3 BOND-003 trial of cretostimogene was accepted at the Society of Urologic Oncology meeting. Despite a cash position sufficient to fund operations until 2027, the company reported a larger net loss this quarter compared to the previous year, influenced by increasing research and development expenses. The company remains optimistic about the potential of cretostimogene while acknowledging various operational challenges.
Read more →CGONCG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates – Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembr
CG Oncology reported strong financial results and positive findings from the CORE-001 study of Cretostimogene Grenadenorepvec combined with Pembrolizumab for treating BCG-unresponsive NMIBC. The company achieved a 54% complete response rate, meeting the primary endpoint, and demonstrated a 75.2% response rate in a separate monotherapy study. Additionally, it initiated an Expanded Access Program to increase patient access to this investigational therapy. Despite these advancements, CG Oncology reported a net loss of $18.9 million, reflecting ongoing high costs associated with clinical trials.
Read more →CGONCG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting – 54% c
CG Oncology has announced promising final results from the Phase 2 CORE-001 study, demonstrating a 54% complete response rate at 24 months for their investigational therapy, cretostimogene, in combination with pembrolizumab for high-risk NMIBC patients. The data shows that 100% of patients were progression-free at 24 months, reinforcing the potential of cretostimogene as an effective treatment option. The findings will be presented at the ASCO 2024 Annual Meeting, where the company aims to highlight the therapy's safety and efficacy, along with plans for future trials.
Read more →CGONCG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive,
CG Oncology has reported its financial results for Q1 2024, highlighting the 75.2% complete response rate of cretostimogene in treating high-risk non-muscle invasive bladder cancer (HR-NMIBC). The company completed a successful $437 million IPO, enhancing its financial runway through 2027. CG Oncology is preparing to present final results from ongoing clinical trials by the end of the year, with notable milestones anticipated. However, the company cautioned that interim results may vary and that reliance on third parties involves inherent risks.
Read more →Competitive Position
How CGON ranks across every disease it competes inCompetitive Position is a premium feature
See how CGON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial